Mediar

Mediar Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class therapies designed to halt or potentially reverse fibrosis. The company utilizes a scientific approach that targets fibrotic mediators—secreted matricellular proteins that modulate myofibroblast biology—which are central to the development of scarring and organ failure in chronically damaged tissues. By combining these novel targets with reliable blood-based biomarkers, Mediar aims to establish a precision medicine framework for treating fibrotic diseases. Their therapeutic platform leverages human IgG1 antibodies, such as MTX-463, which neutralizes WISP1-mediated signaling, and MTX-474, which targets EphrinB2 to address tissue remodeling and cell migration in conditions like idiopathic pulmonary fibrosis and systemic sclerosis.

This research is critical for patients suffering from progressive fibrotic conditions where current treatment options are limited. The company is actively conducting multi-phase clinical trials, including the Phase 2 WISPer trial for MTX-463 and studies focusing on systemic sclerosis. To accelerate its drug discovery and clinical development timelines, Mediar maintains strategic collaborations, such as a global licensing agreement with Eli Lilly and an antibody discovery partnership with Alloy Therapeutics. Based in Boston, Massachusetts, Mediar has secured significant venture capital backing, including Series B financing, to support its mission of pioneering therapies that address the underlying mechanisms of fibrosis across multiple organ systems, including the lungs, liver, and kidneys.